Clinical trial
EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis
NCT00142233 · University Medicine Greifswald, Other · Completed
Key facts
| NCT number | NCT00142233 |
|---|---|
| Title | EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis |
| Official title | Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis |
| Lead sponsor | University Medicine Greifswald, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatitis |
| Intervention type | Dietary Supplement, Drug, Other |
| Interventions | ANTOX (vers.)1.2, Magnesium, Placebo ANTOX (vers)1.2, Placebo Magnesiocard (2.5 mmol) |
| Enrollment | 295 |
| Start date | Jun 6, 2005 |
| Primary completion | Sep 1, 2019 |
| Completion | Sep 1, 2019 |
| First posted | Sep 2, 2005 |
| Last update posted | Mar 27, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: